Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
News|Articles|July 4, 2025
Advancing pediatric health: Key updates and clinical insights from the first half of 2025
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Joshua Fitch, Senior Editor
A look back at the most important FDA approvals, clinical research, and expert perspectives shaping pediatric health care in the first half of 2025.
Advertisement
Advertisement
The first half of 2025 has been marked by significant regulatory milestones in pediatric medicine, with the FDA advancing new therapies, diagnostic tools, and preventive strategies across a range of conditions affecting children and adolescents.
Related to this article
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.
Justin Wheeler, MD, explains how pediatricians can identify constipation across age groups and distinguish overflow incontinence from diarrhea.
Nichole Tyson, MD, outlines how pediatricians can evaluate menstrual concerns, identify red flags, and determine when specialty care is needed.
At AAP 2026, Stephen Bondi, JD, MD, FAAP, outlined steps pediatricians should take after receiving notice of a malpractice claim.
Advertisement
Advertisement